DMAC — DiaMedica Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $97.55m
- $44.66m
- 42
- 26
- 64
- 40
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 11.6 | 12.7 | 13.6 | 14 | 21.3 |
Operating Profit | -11.6 | -12.7 | -13.6 | -14 | -21.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.6 | -12.3 | -13.6 | -13.6 | -19.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.6 | -12.3 | -13.6 | -13.7 | -19.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.6 | -12.3 | -13.6 | -13.7 | -19.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.6 | -12.3 | -13.6 | -13.7 | -19.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.888 | -0.784 | -0.654 | -0.517 | -0.595 |